Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering
Ana I. Romero(Centre National de la Recherche Scientifique), Laurence Zitvogel(Institut Gustave Roussy), Christine Mateus(Centre National de la Recherche Scientifique), Sylvie Rusakiewicz(Inserm), Camillo Porta(University of Pavia), Danila Valmori(Centre National de la Recherche Scientifique), Vichnou Poirier-Colame(Inserm), Nicolas Jacquelot(University of Calgary), Nathalie Chaput(Inserm), Erwan Mortier(Centre National de la Recherche Scientifique), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Kariman Chaba(Centre National de la Recherche Scientifique), Philippe Vielh(Centre National de la Recherche Scientifique), Philippe Dessen(Centre National de la Recherche Scientifique), Anne Caignard(Inserm), Maha Ayyoub(Inserm), Caroline Robert(Université Paris-Sud), Alexander Eggermont(University Medical Center Utrecht), Anne Aupérin(Inserm), Caroline Flament(Inserm), Yannick Jacques(Centre National de la Recherche Scientifique), Sophie Caillat‐Zucman(Inserm)
Cited by 40
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k